RE:RE:Cash burn at AEZS"Should have said enough cash until the end of 2025. Burn rate is about $4M/qtr." Makes you wonder what AEZS's plans are to ramp up spending on their early-stage speculative pipeline programs. How wild are they going to get speculating before they run out of money. They need to put forth a clear plan for what assets they plan to spend on so that the market has a clear understanding of where this is going and the potential commercial payoff. The market isn't in a mood for preclinical/early-stage risk spending. It could be much more favorable to a commercial plan for PGX that delivers a large near-term market opportunity. Do we have a gold standard in the $1 billion yeast beta glucan immune booster market? CZO has designed a trial in animals after results in a test tube suggested a 5X increasee in immune stimulation. Gilles planned to spend $40 million on a 40 million dose per year plant previously. Spending on a program like that with successful PGX scale-up to 100L in hand and a CoQ10 licensing deal could be compelling to the market. Speculative early stage science is viewed right now as worth less than cash and AEZS has a lof of that in its pipeline as it only talks about enough cash into 2025 and trades well below cash.
lscfa wrote: Should have said enough cash until the end of 2025. Burn rate is about $4M/qtr.
| | Cash flow | Net R&D |
| Dec 23 | | |
| Sep 23 | (3,384) | 2,751 |
| June 23 | (4,293) | 1,527 |
| Mar 23 | (4,061) | 2,673 |
| Dec 22 | (3,424) | 2,899 |
| Sep 22 | (3,945) | 2,091 |
| Jun 22 | (4,850) | 2,475 |
| Mar 22 | (1,461) | 1,424 |
| Dec 21 | (2,413) | 1,335 |
| Sep 21 | (1,488) | 801 |
| Jun 21 | (3,635) | 738 |
| Mar 21 | (1,045) | 363 |